CD274 and cancer: Some studies established that it possesses an inhibitory impact on PD-L1 via mediating mRNA degradation [63], while others have shown that doxorubicin, through inhibition of miR-140 expression, upregulates PD-L1 expression in a cancer-type-dependent manner [64].